CoChat

BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members

Hogg, Simon J., Newbold, Andrea, Vervoort, Stephin J., Cluse, Leonie A., Martin, Benjamin P., Gregory, Gareth P., Lefebure, Marcus, Vidacs, Eva, Tothill, Richard W., Bradner, James E., Shortt, Jake, Johnstone, Ricky W. · 2016 · Molecular Cancer Therapeutics
Cited by 71

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Targeting BET bromodomain proteins using small molecules is an emerging anticancer strategy with clinical evaluation of at least six inhibitors now underway. Although MYC downregulation was initially proposed as a key mechanistic property of BET inhibitors, recent evidence suggests that additional antitumor activities are important. Using the Eμ-Myc model of B-cell lymphoma, we demonstrate that BET inhibition with JQ1 is a potent inducer of p53-independent apoptosis that occurs in the absence of effects on Myc gene expression. JQ1 skews the expression of proapoptotic (Bim) and antiapoptotic (BCL-2/BCL-xL) BCL-2 family members to directly engage the mitochondrial apoptotic pathway. Consistent with this, Bim knockout or Bcl-2 overexpression inhibited apoptosis induction by JQ1. We identified lymphomas that were either intrinsically resistant to JQ1-mediated death or acquired resistance following in vivo exposure. Strikingly, in both instances BCL-2 was strongly upregulated and was concomitant with activation of RAS pathways. Eμ-Myc lymphomas engineered to express activated Nras upregulated BCL-2 and acquired a JQ1 resistance phenotype. These studies provide important information on mechanisms of apoptosis induction and resistance to BET-inhibition, while providing further rationale for the translation of BET inhibitors in aggressive B-cell lymphomas. Mol Cancer Ther; 15(9); 2030–41. ©2016 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1535-7163.mct-15-0924

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

  • Selective inhibition of BET bromodomains

    Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., et al. (2010) · Nature · doi:10.1038/nature09504 · Cited by 4,262 · cited 2×

    “We therefore sought to interrogate determinants of apoptosis induction by the prototypical thienodiazepine-based BET-inhibitor, JQ1 (14), using a well-characterized and genetically tractable murine model of aggressiveMyc-driven lymphoma (15).”
    BackgroundMethodSelf-citation
  • Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers

    Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961 · cited 1×

    “BRD4 is associated with almost all active promoters and most active enhancers in both transformed and nontransformed cells (2).”
    BackgroundSelf-citation
  • RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia

    Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870 · cited 1×

    “Therefore, the robust induction of apoptosis in Em-Myc lymphoma differsmechanistically fromother experimental systemswhere decreasedMYC expression appears to be important to mediate the biological effects of BET inhibitors (4, 8, 24).”
    BackgroundSelf-citation
  • Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma

    Chapuy, B., McKeown, M. R., Lin, C. Y., Monti, S., Roemer, M. G. M., Qi, J., Rahl, P. B., Sun, H. H., Yeda, K. T., Doench, J. G., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2013.11.003 · Cited by 735

    Self-citation
  • Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer

    Shu, S., Lin, C. Y., He, H. H., Witwicki, R. M., Tabassum, D. P., Roberts, J. M., Janiszewska, M., Jin Huh, S., Liang, Y., Ryan, J., et al. (2016) · Nature · doi:10.1038/nature16508 · Cited by 632 · cited 2×

    “Two recent studies reported concordant data supporting a role of activated Mol Cancer Ther; 15(9) September 2016 Molecular Cancer Therapeutics2038 www.aacrjournals.org Mol Cancer Ther; 15(9) September 2016 2039 Wnt signaling in mediating resistance to BET inhibitor in MLLrearranged AML (29, 30), whereas another study…”
    BackgroundSelf-citation
  • BET inhibitor resistance emerges from leukaemia stem cells

    Fong, C. Y., Gilan, O., Lam, E. Y. N., Rubin, A. F., Ftouni, S., Tyler, D., Stanley, K., Sinha, D., Yeh, P., Morison, J., et al. (2015) · Nature · doi:10.1038/nature14888 · Cited by 545 · cited 6×

    “Disease progression and secondary JQ1 resistance is associated with Bcl-2 upregulation and RAS pathway activation There has been much recent interest into mechanisms of acquired resistance to BET inhibition, which has proven difficult to engineer in vitro (29, 30).”
    BackgroundSelf-citation

Show all 6 references

Cited by

See all 71

Metadata

Authors
Hogg, S. J., Newbold, A., Vervoort, S. J., Cluse, L. A., Martin, B. P., Gregory, G. P., Lefebure, M., Vidacs, E., Tothill, R. W., Bradner, J. E., Shortt, J., & Johnstone, R. W.
Venue
Molecular Cancer Therapeutics
Published
2016-09-01
Volume
15
Issue
9
Pages
2030-2041
ISSN
  • 1535-7163 (ISSN-L)
  • 1538-8514
OpenAlex
W2471089142
Cited by
71
References
6
FWCI
4.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. https://app.cochat.ai/papers/10.1158/1535-7163.mct-15-0924
The paper
Hogg, S. J., Newbold, A., Vervoort, S. J., Cluse, L. A., Martin, B. P., Gregory, G. P., Lefebure, M., Vidacs, E., Tothill, R. W., Bradner, J. E., Shortt, J., & Johnstone, R. W. (2016). BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-15-0924

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.